SemBioSys Announces Successful Outcome of Personal Care Product Appeal Proceedings at the European Patent Office

Calgary, Canada, November 3 (ots/PRNewswire) -

- Canadian Biotechnology Company's Intellectual Property Position
Strengthened by Decision

TSX symbol: SBS

SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company
developing a broad pipeline of protein-based pharmaceuticals and
non-pharmaceutical products today announced that it has received
notification that the Appeal Board of the European Patent Office
(EPO) has fully revoked European Patent EP 0 680 750 B1 in the name
of Yves Rocher relating to the use of oilbodies in the manufacture
of cosmetics. SemBioSys' DermaSphere(R) Oleosome Technology is
protected by U.S. Patent 6,146,645 and related patents, as well as
European Patent Application 98922563.6.

"We believe this favourable decision confirms and clarifies our
dominant intellectual property position related to the DermaSphere(R)
Oleosome Technology. We place a great deal of importance on properly
protecting our novel oilbody-oleosin technology and this is reflected
by the comprehensive patent portfolio we have been able to
establish," said Andrew Baum, President and CEO of SemBioSys
Genetics Inc.

About DermaSphere(R) Oleosome Technology

The DermaSphere(R) Oleosome Technology was developed by SemBioSys
Genetics Inc. and is based on a natural oil-in-water emulsion derived
from plant oilseeds. The emulsion is comprised of naturally
occurring oil droplets called oleosomes, in which the oil is
surrounded by a shell of phospholipids and unique proteins called
oleosin. The oleosome core provides emolliency, occlusivity and
anti-oxidant effects, and the outer shell provides emulsifying
properties. An oleosome emulsion can be used as the entire
non-active portion of the oil phase of a typical cosmetic
formulation. With this technology, cosmetic formulations can be
prepared under "cold process" conditions, enabling significant
savings in time, energy and inventory management. These unique
attributes of the DermaSphere (R) oleosomes allow the technology to
be used in a wide range of applications including moisturizing
creams, sunscreens, ointments, lotions, eye-care products as well as
many others.

About SemBioSys Genetics Inc. (www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology
company focused on the development, commercialization and production
of biopharmaceuticals and non-pharmaceutical products based on its
plant genetic engineering skills and proprietary oilbody-oleosin
technology platform - the Stratosome(TM) Biologics System. Its two
lead pharmaceutical product candidates are insulin and a
developmental cardiovascular drug called Apo AI. It also has a
series of non-pharmaceutical products addressing animal and
aquaculture health, nutritional oils and human topical markets.
SemBioSys currently has funded partnership agreements with Martek
Biosciences Corporation, Lonza Inc. and Arcadia Biosciences, Inc.

This press release contains forward-looking statements, including,
without limitation, statements containing the words "believe", "may",
"plan ", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws, which reflect the Company's current
expectation and assumptions, and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the
impact of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process and other
risks detailed from time-to-time in the Company's ongoing filings
with the Canadian securities regulatory authorities which filings
can be found at www.sedar.com. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company undertakes no obligation to
publicly update or revise any forward-looking statements either as a
result of new information, future events or otherwise.

ots Originaltext: SemBioSys Genetics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: +1-(403)-717-8767, Fax:
+1-(403)-250-3886, E-mail: bauma@sembiosys.com, Internet:
www.sembiosys.com; Investor Relations: Ross Marshall, The Equicom
Group Inc., Phone: +1-(416)-815-0700 (Ext. 238), Fax:
+1-(416)-815-0080, E-mail: rmarshall@equicomgroup.com